These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 23631720)

  • 1. Design, synthesis, and characterization of new 5-fluorocytosine salts.
    Perumalla SR; Pedireddi VR; Sun CC
    Mol Pharm; 2013 Jun; 10(6):2462-6. PubMed ID: 23631720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enabling tablet product development of 5-fluorocytosine through integrated crystal and particle engineering.
    Perumalla SR; Sun CC
    J Pharm Sci; 2014 Apr; 103(4):1126-32. PubMed ID: 24515970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enabling the Tablet Product Development of 5-Fluorocytosine by Conjugate Acid Base Cocrystals.
    Perumalla SR; Paul S; Sun CC
    J Pharm Sci; 2016 Jun; 105(6):1960-1966. PubMed ID: 27238493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determination of a glucuronide conjugate of flucytosine in humans.
    Chouini-Lalanne N; Malet-Martino MC; Gilard V; Ader JC; Martino R
    Drug Metab Dispos; 1995 Aug; 23(8):813-7. PubMed ID: 7493547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new cocrystal and salts of itraconazole: comparison of solid-state properties, stability and dissolution behavior.
    Shevchenko A; Bimbo LM; Miroshnyk I; Haarala J; Jelínková K; Syrjänen K; van Veen B; Kiesvaara J; Santos HA; Yliruusi J
    Int J Pharm; 2012 Oct; 436(1-2):403-9. PubMed ID: 22750429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and evaluation of miconazole salts and cocrystals for improved physicochemical properties.
    Tsutsumi S; Iida M; Tada N; Kojima T; Ikeda Y; Moriwaki T; Higashi K; Moribe K; Yamamoto K
    Int J Pharm; 2011 Dec; 421(2):230-6. PubMed ID: 21983091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An accelerated stability study of 5-flucytosine in intravenous solution.
    Vermes A; van der Sijs H; Guchelaar HJ
    Pharm World Sci; 1999 Feb; 21(1):35-9. PubMed ID: 10214667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations.
    VandenBussche HL; Johnson CE; Yun J; Patel SA
    Am J Health Syst Pharm; 2002 Oct; 59(19):1853-5. PubMed ID: 12374070
    [No Abstract]   [Full Text] [Related]  

  • 9. Cocrystals of 5-fluorocytosine. I. Coformers with fixed hydrogen-bonding sites.
    Tutughamiarso M; Wagner G; Egert E
    Acta Crystallogr B; 2012 Aug; 68(Pt 4):431-43. PubMed ID: 22810913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tridentate ionic hydrogen-bonding interactions of the 5-fluorocytosine cationic dimer and other 5-fluorocytosine analogues characterized by IRMPD spectroscopy and electronic structure calculations.
    Martens SM; Marta RA; Martens JK; McMahon TB
    J Phys Chem A; 2011 Sep; 115(35):9837-44. PubMed ID: 21755957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 15N-enriched 5-fluorocytosine as a probe for examining unusual DNA structures.
    Sowers LC
    J Biomol Struct Dyn; 2000 Feb; 17(4):713-23. PubMed ID: 10698108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pseudopolymorphs of 5-fluorocytosine.
    Tutughamiarso M; Bolte M; Egert E
    Acta Crystallogr C; 2009 Nov; 65(Pt 11):o574-8. PubMed ID: 19893239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals.
    Gao Y; Gao J; Liu Z; Kan H; Zu H; Sun W; Zhang J; Qian S
    Int J Pharm; 2012 Nov; 438(1-2):327-35. PubMed ID: 22989978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocrystals of 5-fluorocytosine. II. Coformers with variable hydrogen-bonding sites.
    Tutughamiarso M; Egert E
    Acta Crystallogr B; 2012 Aug; 68(Pt 4):444-52. PubMed ID: 22810914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various cytosine/adenine permease homologues are involved in the toxicity of 5-fluorocytosine in Saccharomyces cerevisiae.
    Paluszynski JP; Klassen R; Rohe M; Meinhardt F
    Yeast; 2006 Jul; 23(9):707-15. PubMed ID: 16845689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability.
    Park YJ; Xuan JJ; Oh DH; Balakrishnan P; Yang HJ; Yeo WH; Lee MK; Choi HG; Yong CS
    Arch Pharm Res; 2010 Aug; 33(8):1217-25. PubMed ID: 20803125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a rational vs. high throughput approach for rapid salt screening and selection.
    Collman BM; Miller JM; Seadeek C; Stambek JA; Blackburn AC
    Drug Dev Ind Pharm; 2013 Jan; 39(1):29-38. PubMed ID: 22380522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design.
    Ruge E; Korting HC; Borelli C
    Int J Antimicrob Agents; 2005 Dec; 26(6):427-41. PubMed ID: 16289513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
    Garg A; Singh S
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microwave assisted synthesis and solid-state characterization of lithocholyl amides of isomeric aminopyridines.
    Ahonen KV; Lahtinen MK; Valkonen AM; Dracínský M; Kolehmainen ET
    Steroids; 2011 Feb; 76(3):261-8. PubMed ID: 21130795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.